Connect with us

NEWS

COVID-19: U.S. vaccine trials reaches phase three – Trump

Published

on

THE United States President, Donald Trump has announced that AstraZeneca coronavirus vaccine has reached phase 3 clinical trials in the country and hoped it would be approved for its use.

In a statement released today, Trump said Coronavirus vaccine by AstraZeneca has reached phase 3 clinical trials in the United States and is very close to the end of trials, while hoping that it will be approved for its use against the COVID-19 infection.

“I am pleased to announce that the AstraZeneca vaccine has reached phase three clinical trials. That’s joining another group of vaccines that are very close to the end, and hopefully, approval.”

AstraZeneca company is one of the leaders in the race to develop a coronavirus vaccine against the COVID-19 infection that has affected millions across the world. Other companies that have coronavirus vaccines in phase 3 trials include Moderna Inc and Pfizer Inc.

In an address at the White House, Trump said the United States managed to reach this stage in the progress of a coronavirus vaccine in a few months when it would have otherwise taken months.

“In the United States, we’re doing things that nobody thought would have been even possible. This is a process that would have taken, in some cases, years, and we did it in a matter of months,” Trump said.

He added that America remains on track to deliver a coronavirus vaccine in record time, insisting that a new coronavirus cases in the country have declined by 38 per cent.

“Over the last month, new cases in the United States have declined by 38 per cent. Last week, we announced a breakthrough in testing that will allow us to have over 150 million rapid, point-of-care tests. These tests return results in less than 15 minutes, and many

will be deployed to nursing homes.”

Continuing, “we are focusing very strongly on nursing homes, assisted living facilities and other locations that serve high-risk populations. So we’re going to have the 15-minute and less tests, and we will have 150 million rapid point-of-care tests.”

The National Institute of Health (NIH) separately announced on yesterday that phase 3 clinical trials of AstraZeneca’s coronavirus vaccine, known as AZD1222, will enroll approximately 30,000 adult volunteers at 80 sites in the U.S. to see if the COVID-19 vaccine can prevent the infection.

The UK-based global biopharmaceutical company, AstraZeneca, is leading the coronavirus vaccine trials as a regulatory sponsor.

According to National Institute of Allergy and Infectious Diseases (NIAID) Director Anthony Fauci, “safe and effective vaccines will be essential to meet the global need for widespread protection against coronavirus,”

Fauci added, “positive results from preclinical research supported the rapid development of this coronavirus vaccine candidate, which has also showed promise in early-stage clinical trials.”

Source says, Oxford University’s Jenner Institute and Oxford Vaccine Group have developed AZD1222. The candidate coronavirus vaccine was licensed to AstraZeneca for further development.

It will be recalled that the United States has so far recorded 6,030,782 coronavirus cases and 183,596 fatalities — both the numbers highest in the world.

The phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by the U.S Health and Human Services, which aims at accelerating the development and manufacturing of medical countermeasures for the novel coronavirus and delivering 300 million doses of an effective vaccine by January 2021.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending